$9.85 $0.38 (4.0%)

04:30 PM EST on 01/17/20

Clovis Oncology (NASDAQ:CLVS)

CAPS Rating: 2 out of 5

Current Price $9.85 Mkt Cap $715.0M
Open $9.37 P/E Ratio 0.00
Prev. Close $9.85 Div. (Yield) $0.00 (0.0%)
Daily Range $9.36 - $10.19 Volume 13,936,559
52-Wk Range $8.11 - $11.28 Avg. Daily Vol. 12,548,372

Caps

How do you think NASDAQ:CLVS will perform against the market?

Add Stock to CAPS Watchlist

All Players

68 Outperform
22 Underperform
 

All-Star Players

18 Outperform
9 Underperform
 

Wall Street

4 Outperform
0 Underperform
 

Top NASDAQ:CLVS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.61)
Submitted February 16, 2016

Clovis isn't exactly flying under the radar ahead of the rociletinib Ad Comm on April 12. There's lots of commentary on the drug's prospects for approval, most of it negative. Of course, the shocking aspect of the whole situation was the blase way in… More

TerryHogan (99.97)
Submitted October 10, 2018

The financials on this one are fishier than a murder mystery dinner theater in Newfoundland. You can expect SG&A to go up in line with revenue a bit, but why does R&D increase with every revenue increase to wipe out all profits? I'm not saying… More

NASDAQ:CLVS VS S&P 500 (SPY)

Fools bullish on NASDAQ:CLVS are also bullish on:

Fools bearish on NASDAQ:CLVS are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CLVS.

Recs

0
Member Avatar Bigsef77 (68.94) Submitted: 10/2/2018 10:16:34 AM : Outperform Start Price: $12.96 NASDAQ:CLVS Score: -185.78

Clovis Oncology stock rises 10% premarket after 'breakthrough' designation from FDA

,MarketWatch•October 2, 2018
Clovis Oncology Inc. shares rose nearly 10% in Tuesday premarket trade after the company's cancer drug Rubraca got a "breakthrough therapy" designation from the Food and Drug Administration. The designation could expedite the development and review of Rubraca by the FDA for BRCA1/2-mutated metastatic castration-resistant prostate cancer. The company plans to present the phase 2 trial data that "served as the basis of our [breakthrough therapy designation] at the [European Society for Medical Oncology] conference later this month," Clovis Chief Executive Patrick Mahaffy said. Metastatic castration-resistant prostate cancer refers to a type of cancer that has spread beyond the prostate and continues to spread in spite of treatments intended to manage the disease. Called mCRPC, it is incurable and usually associated with poor prognosis, according to Clovis. Clovis is also testing Rubraca in a number of other types of cancer, including in combination with a Bristol-Myers Squibb immunotherapy; the drug has not been approved in the U.S. Clovis shares have dropped 35.5% over the last three months, compared with a 7.3% rise in the S&P 500 and a 9.6% rise in the Dow Jones Industrial Average .

Recs

0
Member Avatar Capitalism (86.10) Submitted: 2/26/2018 1:20:40 PM : Outperform Start Price: $55.12 NASDAQ:CLVS Score: -101.92

Richard Marzouka (SA) pick.

Recs

0
Member Avatar LifeScientist (25.26) Submitted: 2/17/2016 3:19:38 PM : Outperform Start Price: $19.78 NASDAQ:CLVS Score: -122.58

technical near term bottom and nice upside two day trend; no insider selling of late since the drop last Nov. ( however no buying reported for 12 mos. ) top fools ZZlangerhaus and Seth15701 like it and former had a reasonable analysis .... Note, due to announce on Feb 25, so have to decide whether to hold it through earnings, but street's got a good negative expect of cash burn. Credit Suisse has picked it up with an analysis and an outperform since the Nov price drop.

Leaderboard

Find the members with the highest scoring picks in CLVS.

Score Leader

anchak

anchak (99.93) Score: +387.02

The Score Leader is the player with the highest score across all their picks in CLVS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
yosemitebean 39.39 10/29/2019 Outperform 5Y $3.06 +221.90% +9.62% +212.28 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Under5 < 20 10/11/2019 Outperform 5Y $3.21 +206.85% +12.08% +194.78 0 Comment
kurzzz 81.90 6/25/2013 Underperform 5Y $65.00 -84.85% +109.52% +194.37 0 Comment
ExpressRocks 92.55 6/25/2013 Underperform 5Y $63.88 -84.58% +109.46% +194.03 0 Comment
bluebare 47.20 6/14/2013 Underperform 5Y $69.38 -85.80% +103.72% +189.53 0 Comment
kevian 90.04 6/3/2013 Underperform 1Y $71.74 -86.27% +102.31% +188.58 0 Comment
IBDContrarian 67.66 4/8/2013 Underperform 5Y $29.05 -66.09% +113.85% +179.95 1 Comment
goldminingXpert 28.55 5/13/2013 Underperform NS $37.75 -73.91% +102.78% +176.69 0 Comment
MFBurritoSquat 92.43 11/30/2012 Underperform 3M $15.81 -37.70% +133.77% +171.47 0 Comment
KidJones 34.01 12/3/2012 Underperform 5Y $15.59 -36.80% +134.47% +171.26 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CLVS.